Sandu Pharmaceuticals Ltd
Sandu Pharmaceuticals Ltd (SANDUPHQ) last reported results for the quarter ended Mar 2025, with sales of ₹14.07 crore and net profit of ₹0.33 crore. The stock last traded at ₹37.3, a market capitalisation of ₹36 crore, on a P/E of 23.2. Over the past 52 weeks the stock has ranged between ₹30 and ₹50. Figures are as of 6 Oct 2026 and are not real time.
Sandu Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹37.3
- Market cap
- ₹36 cr
- Stock P/E
- 23.2
- Book value
- ₹43.5
- ROE
- 3.75%
- ROCE
- 5.47%
- Dividend yield
- 2.68%
- 52w high / low
- 50.0/30.0
Metrics as of 6 Oct 2026. Not real time.
Track Sandu Pharmaceuticals Ltd
Cruxal reads every Sandu Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Sandu Pharmaceuticals Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 1%
- TTM
- 0%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -1%
- TTM
- 6%
- 10 Years
- 2%
- 5 Years
- -7%
- 3 Years
- -20%
- 1 Year
- -17%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 4%
- Last Year
- 4%
Sandu Pharmaceuticals Ltd quarterly results
In the quarter ended Mar 2025, sales were ₹14.07 cr, down 9.8% from ₹15.6 cr a year earlier. Net profit was ₹0.33 cr, down 44.1% year on year.
| ₹ crore | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 17.66 | 16.61 | 17.43 | 15.6 | 17.05 | 17.7 | 18.37 | 14.07 |
| Expenses | 17.31 | 15.79 | 16.92 | 14.99 | 16.64 | 16.79 | 17.37 | 13.62 |
| Operating profit | 0.35 | 0.82 | 0.51 | 0.61 | 0.41 | 0.91 | 1 | 0.45 |
| OPM % | 1.98% | 4.94% | 2.93% | 3.91% | 2.40% | 5.14% | 5.44% | 3.20% |
| Other income | 0 | 0.09 | 0.03 | 0.31 | 0.04 | 0.03 | 0.02 | 0.07 |
| Interest | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | 0.03 | 0.03 | 0.03 |
| Depreciation | 0.12 | 0.13 | 0.14 | 0.19 | 0.16 | 0.17 | 0.19 | 0.15 |
| Profit before tax | 0.21 | 0.77 | 0.38 | 0.72 | 0.27 | 0.74 | 0.8 | 0.34 |
| Tax % | 47.62% | 27.27% | 44.74% | 16.67% | 40.74% | 32.43% | 30.00% | 2.94% |
| Net profit | 0.11 | 0.55 | 0.21 | 0.59 | 0.17 | 0.5 | 0.56 | 0.33 |
| EPS (₹) | 0.11 | 0.57 | 0.22 | 0.61 | 0.18 | 0.52 | 0.58 | 0.34 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Sandu Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Sales | 65.5 | 65.35 | 67.28 | 67.19 |
| Operating profit | 2.88 | 2.48 | 2.3 | 2.76 |
| OPM % | 4.40% | 3.79% | 3.42% | 4.11% |
| Net profit | 1.59 | 1.52 | 1.46 | 1.55 |
| EPS (₹) | 1.80 | 1.57 | 1.51 | 1.60 |
TTM is the trailing twelve months to the most recent quarter.
Sandu Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Equity capital | 8.81 | 9.66 | 9.66 | 9.66 |
| Reserves | 27.66 | 29.58 | 30.93 | 32.36 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 |
| Other liabilities | 12.81 | 14.93 | 11.82 | 13.71 |
| Total liabilities | 49.28 | 54.17 | 52.41 | 55.73 |
| Fixed assets | 16.00 | 16.62 | 17.88 | 18.15 |
| CWIP | 0.48 | 0.42 | 0.00 | 0.00 |
| Investments | 9.11 | 9.65 | 10.42 | 11.22 |
| Other assets | 23.69 | 27.48 | 24.11 | 26.36 |
| Total assets | 49.28 | 54.17 | 52.41 | 55.73 |
As reported by the company. Total assets equal total liabilities by construction.
Sandu Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Cash from operations | 0.95 | 0.22 | 0.76 | 0.95 |
| Cash from investing | -5.47 | 0.54 | -1.31 | -0.19 |
| Cash from financing | 0.93 | 0.58 | -0.72 | -0.46 |
| Net cash flow | -3.59 | 1.34 | -1.27 | 0.30 |
| Free cash flow | 0.11 | -0.85 | -0.67 | 0.01 |
| CFO / operating profit | 64% | 37% | 55% | 55% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Sandu Pharmaceuticals Ltd operating ratios
| Per year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| ROCE % | — | 6.05% | 5.36% | 5.47% |
| Debtor days | 22.23 | 26.75 | 26.42 | 25.86 |
| Inventory days | 115.06 | 167.70 | 137.28 | 160.90 |
| Days payable | 69.63 | 98.30 | 47.07 | 51.05 |
| Cash conversion cycle | 67.67 | 96.15 | 116.63 | 135.70 |
| Working capital days | 42.41 | 52.33 | 56.75 | 62.80 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Sandu Pharmaceuticals Ltd shareholding pattern
Promoters held 37.79% at Jun 2026, down from 42.91% at Jun 2025. DIIs 0.01%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 42.91% | 42.91% | 42.91% | 42.91% | 42.91% | 37.79% | 37.79% | 37.79% |
| DIIs | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 57.09% | 57.09% | 57.09% | 57.08% | 57.09% | 62.19% | 62.20% | 62.20% |
| No. of shareholders | 10,246 | 10,333 | 10,287 | 10,226 | 10,284 | 10,284 | 10,298 | 10,268 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Sandu Pharmaceuticals Ltd corporate filings
- Sandu Pharmaceuticals updates director name from Dr Neeti Madan Kapre to Dr Neeti GuptaCompany Updatelow impact
Cruxal's analysis: Sandu Pharmaceuticals Ltd has formally notified a change in the name of its director…
Read the full analysis - compliance certificate under Reg 74(5) of SEBI(DP) Regulation for Q ended 30th September 2026Company Updatelow impact
- Sandu Pharmaceuticals issues notice for physical security holders to furnish PAN and KYC detailsCompany Updatelow impact
Cruxal's analysis: On September 30, 2026, Sandu Pharmaceuticals Ltd, a small-cap company with a market cap…
Read the full analysis - Intimation about closure of trading window for Quarter ended 30th September 2026Insider Trading / SASTlow impact
- Sandu Pharmaceuticals Limited Announces Board Reconstitution: New CMD and Independent Director AppointedCompany Updatelow impact
Cruxal's analysis: Sandu Pharmaceuticals Limited has formally announced the redesignation of Shri Balram…
Read the full analysis - Sandu Pharmaceuticals Limited Announces Appointment of New Statutory AuditorsCompany Updatelow impact
Cruxal's analysis: Sandu Pharmaceuticals Limited has appointed M/s. Dave & Dave, Chartered Accountants, as…
Read the full analysis - Sandu Pharmaceuticals Limited Announces Successful Conclusion of 41st Annual General Meeting and Passing of All ResolutionsAGM/EGMlow impact
Cruxal's analysis: Sandu Pharmaceuticals Limited has successfully concluded its 41st Annual General Meeting…
Read the full analysis - Sandu Pharmaceuticals Limited concludes 41st Annual General Meeting with key resolutions passedAGM/EGMlow impact
Cruxal's analysis: Sandu Pharmaceuticals Limited has successfully concluded its 41st Annual General Meeting…
Read the full analysis - Sandu Pharmaceuticals Ltd announces special window for re-lodgement of physical share transfer requestsCompany Updatelow impact
Cruxal's analysis: Sandu Pharmaceuticals has published a newspaper notice regarding the opening of a special…
Read the full analysis - Sandu Pharmaceuticals Ltd announces Annual General Meeting and E-voting detailsCompany Updatelow impact
Cruxal's analysis: Sandu Pharmaceuticals has published a newspaper advertisement to inform shareholders…
Read the full analysis - Sandu Pharmaceuticals Ltd issues notice to shareholders regarding annual report accessCompany Updatelow impact
Cruxal's analysis: Sandu Pharmaceuticals Ltd has issued a communication to shareholders whose email…
Read the full analysis - Sandu Pharmaceuticals Ltd releases 41st Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Sandu Pharmaceuticals has filed its 41st Annual Report for the financial year ending…
Read the full analysis - Sandu Pharmaceuticals Limited Announces 41st AGM, Dividend Declaration, and Leadership RestructuringAGM/EGMmedium impact
Cruxal's analysis: Sandu Pharmaceuticals Limited has scheduled its 41st Annual General Meeting for September…
Read the full analysis - Sandu Pharmaceuticals Ltd announces newspaper publication regarding Annual Report dispatchCompany Updatelow impact
Cruxal's analysis: Sandu Pharmaceuticals Ltd has published a mandatory newspaper advertisement confirming…
Read the full analysis - Sandu Pharmaceuticals Limited Reports Q1 FY2027 Financial ResultsCompany Updatelow impact
Cruxal's analysis: Sandu Pharmaceuticals Limited reported its unaudited financial results for the quarter…
Read the full analysis - Sandu Pharmaceuticals Ltd seeks shareholder approval for material related party transactionsCompany Updatelow impact
Cruxal's analysis: Sandu Pharmaceuticals has announced that it will seek shareholder approval for material…
Read the full analysis - Sandu Pharmaceuticals Ltd files statement of deviation and utilisation of funds for quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Sandu Pharmaceuticals Ltd has submitted its statement of deviation or variation in the…
Read the full analysis - Sandu Pharmaceuticals Ltd schedules Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Sandu Pharmaceuticals Ltd has issued an intimation regarding the date of its upcoming…
Read the full analysis - Sandu Pharmaceuticals Ltd announces record date for corporate actionCorp. Actionlow impact
Cruxal's analysis: Sandu Pharmaceuticals Ltd has issued an intimation regarding a record date for a…
Read the full analysis - Sandu Pharmaceuticals Reports Q1 FY27 Financial Results and Announces AGM DetailsCompany Updatemedium impact
Cruxal's analysis: Sandu Pharmaceuticals Limited reported Q1 FY27 revenue from operations of 16.39 crore…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.